Company created a large panel of HCAs and established a new way to quantify the biological activity of drug metabolites.
Odyssey Thera reports that it achieved two milestones under a collaboration with Pfizer, thus enhancing its protein-fragment complementation assay (PCA) technology. This product measures pathway activity within living human cells.
The first milestone payment stemmed from the creation of a large panel of high-content assays. An additional milestone was earned for establishing a system to quantify the biological activity of drug metabolites in living human cells.
Odyssey Thera entered into a broad agreement with Pfizer in September 2006 following the successful completion of two prior partnerships. The 2006 deal was inked to utilize Odyssey Thera’s PCA technology to evaluate the selectivity of Pfizer compounds. Besides an upfront fee, Pfizer agreed to pay research and capital expenditure funding as well as success-based milestones.
Under the terms of the current multiyear deal, Pfizer made an upfront payment and agreed to provide research and capital expenditure funding as well as to make milestone payments.
